NervGen Pharma Corp. filed a Form 6-K on November 18, 2026, disclosing the appointment of Dr. Sam Jackson as Chief Medical Officer, effective December 7, 2026, along with the full terms of his compensation and equity awards.
Key Highlights
- Appointment effective December 7, 2026: Dr. Sam Jackson, age 60, will serve as Chief Medical Officer, reporting directly to the Chief Executive Officer.
- Base salary of $525,000: Dr. Jackson will receive an annualized base salary of $525,000 under the terms of the offer letter signed November 16, 2026.
- Sign-on bonus of $208,000: Payable in two installments: $100,000 following the effective date and $108,000 on or after March 31, 2027, subject to continued employment.
- Stock options for up to 1,156,135 common shares: Options vest over four years, with 25.0% on the first anniversary and the remaining 75.0% in thirty-six substantially equal monthly installments thereafter.
- 50,000 restricted share units: Vest in full only if at least 150 participants have been randomized and enrolled in the RESTORE study on or before August 1, 2027, subject to continued service.
- Annual bonus target of 40% of base salary: Begins with fiscal year 2027, based on Company and individual performance objectives established by the Compensation Committee.
NervGen Discloses Jackson's Compensation Structure and Prior Experience
According to the filing, Dr. Jackson brings more than 20 years of industry experience in clinical development for neurologic, immunologic, and ophthalmic programs. He previously served as Chief Medical Officer of Aditum Bio from August 2025 to December 2026, Chief Medical Officer of Neuron23 Inc. from April 2022 to May 2025, and Chief Medical Officer (interim) / Senior Vice President Clinical Development at Alector, Inc. (Nasdaq: ALEC) from April 2020 to April 2022. The filing notes he is a board-certified physician with an MD from the University of Pennsylvania, an MBA from The Wharton School at the University of Pennsylvania, and a BA from Stanford University.
The filing discloses that the stock options will be exercisable for ten years, with an exercise price equal to the closing price of NervGen's common shares on the Nasdaq Capital Market on December 7, 2026. The company is listed on NASDAQ:NGEN. The 50,000 restricted share units are conditioned on a clinical enrollment milestone in the RESTORE study by August 1, 2027, and Dr. Jackson's continued service. All incentive-based compensation is stated to be subject to the Company's Compensation Recovery Policy.
The filing also details severance provisions. If Dr. Jackson's employment is terminated without cause or for good reason outside a change in control period, NervGen U.S. is obligated to continue base salary payments for nine months, pay any earned but unpaid prior-year bonus, and cover COBRA premiums for up to nine months. Within three months before or twelve months after a change in control, he would be entitled to a lump sum equal to twelve months of base salary plus 100% of his target bonus, COBRA premiums for up to twelve months, and full vesting of outstanding unvested time-based equity awards. Severance benefits are conditioned on execution of a general release of claims, according to the filing.
What Was Disclosed
NervGen Pharma Corp. reported the appointment of Dr. Sam Jackson as Chief Medical Officer effective December 7, 2026, and disclosed the full terms of his offer letter and sign-on bonus agreement, including salary, bonus, stock options, and severance arrangements.



Please wait processing your request...